welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
Study of DS-5141b in Patients With Duchenne Muscular Dystrophy
study id #: NCT02667483
condition: Duchenne Muscular Dystrophy
status: active, not recruitingpurpose:
This is a phase I/II study to evaluate the safety, tolerability, efficacy, and pharmacokinetic (PK) profile of DS-5141b in patients with Duchenne muscular dystrophy (DMD) amenable to exon 45 skipping and to determine the dosage for subsequent studies.
mechanism of action: Exon-skipping to promote dystrophin production
last updated: July 08, 2019
start date: October 2015
estimated completion: December 2019
phase of development: Phase 1/Phase 2
size / enrollment: 7
- Number of participants with treatment-emergent adverse events (TEAEs) by the end of the trial [Time Frame: 48 Weeks of Part 2-Extension]
TEAEs are adverse events (including clinically significant laboratory values) temporally associated with use of DS-5141b, whether or not attributable to the product.
- Maximum concentration (Cmax) of DS-5141b [Time Frame: Week 48 of Part 2-Extension]
- Area under the curve (AUC) for DS-5141b [Time Frame: Week 48 of Part 2-Extension]
- Time to maximum concentration (Tmax) of DS-5141b [Time Frame: Week 48 of Part 2-Extension]
- Half-life (T1/2) of DS-5141b [Time Frame: Week 48 of Part 2-Extension]
- Dystrophin protein expression in muscle tissue [Time Frame: Week 48 of Part 2-Extension]
- Production of exon 45-skipped dystrophin mRNA in muscle tissue [Time Frame: Week 48 of Part 2-Extension]
• Confirmation of out-of-frame deletion(s) that could be corrected by dystrophin gene exon 45 skipping.
• Intact muscles of adequate quality for biopsy to allow evaluation of the efficacy of the study drug.
• Boys aged from 5 years to <11 years.
• Patients able to walk at least 325 meters in the 6-minutes walk test.
• Glucocorticoid-naive patients, or patients who have used glucocorticoids for at least 6 months prior to enrollment in this study with no dose changes for at least 3 months prior to enrollment
• A genetic mutation that cannot be expected the expression of dystrophin protein by dystrophin gene exon 45 skipping.
• A concurrent illness other than DMD that can cause muscle weakness and/or impairment of motor function.
• Current or history of severe disorder.
• Left ventricular ejection fraction (LEVF) <55%.
• Corrected QT interval (QTc) >0.45 sec.
Microdystrophin Gene Transfer Study in Adolescents and Children With DMDThis is a randomized, controlled, open-l...
Phase II Study of NPC-14 (Arbekacin Sulfate) to Explore Safety, Tolerability, and Efficacy in Duchenne Muscular Dyst...Duchenne Muscular Dystrophy (DMD) is inh...
Edasalonexent could reduce functional decline in boys with DMD, MoveDMD phase 2 results suggestResults of the Phase 2 MoveDMD trial sho...
Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-infl...We report a first-in-patient study of va...
Exploratory Study of NS-065/NCNP-01 in DMDThis study is designed to assess the saf...
A Phase IIa Study of TAS-205 for Duchenne Muscular DystrophyThe objective of this study is to evalua...
Phase 1 Study of Edasalonexent (CAT-1004), an Oral NF-κB Inhibitor, in Pediatric Patients with Duchenne Muscular Dy...Background: Edasalonexent is an orally ...
Roche Letter to the Duchenne CommunityBy now, many have heard about Pfizer's d...
Capricor Therapeutics Announces Positive Results from its Interim Analysis in the HOPE-2 Trial to Treat Patients wit...Capricor Therapeutics, Inc. (NASDAQ: CAP...